See What HealthDay Can Do For You
Contact Us

High-Dose Chemo Improves Breast Cancer Survival

Four-year survival ranks better than conventional chemo regimen

TUESDAY, Dec. 6 (HealthDay News) -- A rapidly cycled tandem high-dose chemotherapy regimen following conventional chemotherapy may improve the four-year survival of breast cancer patients, according to a report in the Dec. 3 issue of The Lancet.

Ulrike Anneliese Nitz, M.D., from the University Hospital Dusseldorf, Germany, and colleagues randomly assigned 403 breast cancer patients with at least nine positive nodes to either a high-dose regimen including two standard-dose courses followed by two high-dose courses of epirubicin and cyclophosphamide, or a conventional regimen of the drugs with adjuvant therapy.

The authors found the four-year event-free survival rate of the 201 patients assigned to the high-dose regimen was 60%, significantly higher than the 44% rate for patients assigned conventional chemotherapy. The overall survival rate for the two groups was 75% and 70%, respectively.

According to Nitz and colleagues, previous studies did not find any benefit of high-dose chemotherapy, however, these were varied in their design. "Nevertheless, the superiority of high-dose chemotherapy in our trial suggests that this strategy remains valid for further investigation," they write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.